2022
Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia
Goshua G, Sinha P, Kunst N, Pischel L, Lee AI, Cuker A. Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia. American Journal Of Hematology 2022, 98: 122-130. PMID: 35147241, PMCID: PMC9365880, DOI: 10.1002/ajh.26497.Peer-Reviewed Original ResearchConceptsThrombopoietin receptor agonistsChronic immune thrombocytopeniaSecond-line therapyImmune thrombocytopeniaEarly useCurrent practice trendsProbabilistic sensitivity analysesCost-effective treatmentFirst cost-effectiveness analysisCost-effectiveness analysisU.S. health systemLack of evidenceEarly splenectomyHematology (ASH) guidelinesReceptor agonistCurrent guidelinesSplenectomyClinical practicePractice trendsTherapyHealth systemCost-effective strategyRituximabThrombocytopeniaAmerican SocietyAdenovirus-Based Vaccines and Thrombosis in Pregnancy: A Systematic Review and Meta-analysis
Pischel L, Patel KM, Goshua G, Omer SB. Adenovirus-Based Vaccines and Thrombosis in Pregnancy: A Systematic Review and Meta-analysis. Clinical Infectious Diseases 2022, 75: 1179-1186. PMID: 35134164, PMCID: PMC9383370, DOI: 10.1093/cid/ciac080.Peer-Reviewed Original ResearchConceptsAdenovirus-vectored vaccinePregnant womenVector vaccinesSystematic reviewGeneral populationAdenovirus vector-based vaccinesClinical trial populationsVector-based vaccinesCrucial risk factorVaccine recipientsHypercoagulable stateTrial populationRisk factorsClinical trialsJohnson vaccineRare caseVaccine componentsThrombocytopeniaVaxzevria vaccineMeta-AnalysisVaccine developmentVaccinePotential associationCoagulopathyInfectious diseases
2020
Diagnosis of oesophageal mucormycosis managed with medical therapy alone
Ringer M, Pischel L, Azar MM. Diagnosis of oesophageal mucormycosis managed with medical therapy alone. BMJ Case Reports 2020, 13: e236869. PMID: 33093060, PMCID: PMC7583061, DOI: 10.1136/bcr-2020-236869.Peer-Reviewed Original ResearchConceptsIdarubicin/cytarabineLiposomal amphotericin BAcute myeloid leukemiaFebrile neutropeniaInduction chemotherapyPosaconazole therapyClinical characteristicsMedical therapySurgical morbiditySurgical interventionAggressive infectionDevastating manifestationMyeloid leukemiaCT scanInvasive moldsMucormycosisLebanese menAmphotericin BPatientsDiagnosisTherapyReportOdynophagiaNeutropeniaThrombocytopenia